Clinical Trial Update: A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing bevacizumab combined with first- or second-line therapy in patients with treated brain metastases from non-squamous non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer, Brain Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2011-06-22